What is driving the pre-market jump in 4888.T stock?

The pre-market lift reflects heavy volume and renewed investor interest in Stella Pharma’s BNCT program, plus speculative flows into small-cap biotech. No formal press release was cited; traders are watching clinical and partnership news ahead of the May 12 earnings date.

What targets and risks should traders use for 4888.T stock?

Near-term resistance sits at **JPY 646.00** with a breakout target **JPY 700.00** (+15.70%). Key downside support is the 50-day average **JPY 354.46** (-41.43%). Major risks include negative EPS **-5.04** and very high valuation ratios.

How does Meyka AI evaluate 4888.T stock and what is the forecast?

Meyka AI rates 4888.T **70.35/100 (B+, BUY)**. The forecast model projects a yearly price of **JPY 302.74**, which implies **-49.96%** versus the current **JPY 605.00**. Forecasts are model-based and not guarantees.

Should 4888.T stock be in a diversified biotech portfolio?

4888.T stock can offer high upside tied to clinical catalysts but carries elevated valuation and volatility. Use it as a small, sized position within a diversified biotech sleeve and monitor liquidity and news closely.

JP Stocks

Pre-Market Top Gainer 21 Mar 2026: Stella Pharma (4888.T) JPX +8.04% ahead of 646.00 JPY test

ByHuzaifa Zahoor March 20, 2026March 20, 2026

4888.T stock leads Japan’s pre-market movers on 21 Mar 2026 after a sharp intraday lift. Stella Pharma Corporation (4888.T) on JPX trades at JPY 605.00, up 8.04% from the previous close of JPY 560.00, with volume at 8,573,300 shares. The move puts the share price within striking distance of the year high JPY 646.00. We examine drivers, valuation, technical triggers, and Meyka AI’s forecast to explain why Stella Pharma is a top gainer in the pre-market session.